Insights

Loading spinner
Gathering insights about Cara Therapeutics

Cara Therapeutics Tech Stack

Cara Therapeutics uses 8 technology products and services including WordPress, Google Font API, Swiper, and more. Explore Cara Therapeutics's tech stack below.

  • WordPress
    Content Management System
  • Google Font API
    Font Scripts
  • Swiper
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • web-vitals
    Javascript Libraries
  • Office 365
    Office Suites
  • Akamai Web Application Protector
    Security

Media & News

Cara Therapeutics's Email Address Formats

Cara Therapeutics uses at least 1 format(s):
Cara Therapeutics Email FormatsExamplePercentage
first.last@caratherapeutics.comJohn.Doe@caratherapeutics.com
50%
flast@caratherapeutics.comJDoe@caratherapeutics.com
25%
first@caratherapeutics.comJohn@caratherapeutics.com
13%
f.last@caratherapeutics.comJ.Doe@caratherapeutics.com
12%

Frequently Asked Questions

Where is Cara Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Cara Therapeutics's main headquarters is located at 4 Stamford Plaza 9th Floor Stamford, Connecticut 06902 US. The company has employees across 3 continents, including North AmericaEuropeSouth America.

What is Cara Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Cara Therapeutics's main corporate office by phone at +1-203-567-1500. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Cara Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Cara Therapeutics is a publicly traded company; the company's stock symbol is CARA.

What is Cara Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Cara Therapeutics's official website is caratherapeutics.com and has social profiles on LinkedIn.

How much revenue does Cara Therapeutics generate?

Minus sign iconPlus sign icon
As of March 2024, Cara Therapeutics's annual revenue reached $23M.

What is Cara Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Cara Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cara Therapeutics have currently?

Minus sign iconPlus sign icon
As of March 2024, Cara Therapeutics has approximately 84 employees across 3 continents, including North AmericaEuropeSouth America. Key team members include Chief Strategy Officer & Head Of Investor Relations: I. F.Chief Financial Officer: R. M.Chief Medical Officer: J. S.. Explore Cara Therapeutics's employee directory with LeadIQ.

What industry does Cara Therapeutics belong to?

Minus sign iconPlus sign icon
Cara Therapeutics operates in the Biotechnology Research industry.

What technology does Cara Therapeutics use?

Minus sign iconPlus sign icon
Cara Therapeutics's tech stack includes WordPressGoogle Font APISwiperjQueryModernizrweb-vitalsOffice 365Akamai Web Application Protector.

What is Cara Therapeutics's email format?

Minus sign iconPlus sign icon
Cara Therapeutics's email format typically follows the pattern of . Find more Cara Therapeutics email formats with LeadIQ.

How much funding has Cara Therapeutics raised to date?

Minus sign iconPlus sign icon
As of March 2024, Cara Therapeutics has raised $40M in funding. The last funding round occurred on Nov 02, 2023.

When was Cara Therapeutics founded?

Minus sign iconPlus sign icon
Cara Therapeutics was founded in 2004.
Cara Therapeutics

Cara Therapeutics

Biotechnology ResearchConnecticut, United States51-200 Employees

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. 

Section iconCompany Overview

Headquarters
4 Stamford Plaza 9th Floor Stamford, Connecticut 06902 US
Phone number
+1-203-567-1500
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
CARA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
51-200

Section iconFunding & Financials

  • $40M

    Cara Therapeutics has raised a total of $40M of funding over 10 rounds. Their latest funding round was raised on Nov 02, 2023.

  • $10M$50M

    Cara Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $40M

    Cara Therapeutics has raised a total of $40M of funding over 10 rounds. Their latest funding round was raised on Nov 02, 2023.

  • $10M$50M

    Cara Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.